A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel ...
Oncology Media Relations oncology_media_relations@its.jnj.com Investor contact: Jessica Margevich investor-relations@its.jnj.com ...
Bayer filed a lawsuit against Johnson & Johnson and its Janssen Biotech unit, alleging that marketing claims regarding the superiority of J&J's Erleada prostate-cancer drug versus Bayer's Nubeqa are ...
Good morning, everybody. My name is Kyahn Williamson, SVP of Investor Relations and Corporate Communications at Telix. And we're very pleased to welcome you today to our investor call and webcast to ...
BioNTech and partner DualityBio are accelerating the development of their B7-H3 antibody-drug conjugate into a phase 3 trial for metastatic castration-resistant prostate cancer (mCRPC). | BioNTech and ...
10d
Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) to be completed by our partner Jazz in first-line HER2-positive ...
BioNTech on track for a catalyst-rich year with six late-stage data readouts expected across immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies Increased focus on PD-L11/VEGF-A ...
BioNTech on track for a catalyst-rich year with six late-stage data readouts expected across immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies Increased focus on PD-L11/VEGF-A ...
Q4 2025 Earnings Call March 3, 2026 4:30 PM ESTCompany ParticipantsPatrick Soon-Shiong - Founder, Executive Chairman and ...
Final phase 3 EORTC 1333/PEACE-3 data show enzalutamide plus radium-223 extends OS and radiographic progression-free survival in mCRPC with bone metastases. Final data from the phase 3 EORTC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results